D-0344-2025 Class II Ongoing
FDA drug recall D-0344-2025 was initiated by Glenmark Pharmaceuticals Inc., USA on Mar 13, 2025 and is designated Class II. Reason for recall: CGMP Deviations The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 16, 2025
- Initiation Date
- Mar 13, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Clindamycin Hydrochloride Capsules, USP, 300mg, 100-count bottles, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc. USA, Mahwah, NJ 07430.NDC# 68462-144-01
Reason for recall
CGMP Deviations
Distribution pattern
U.S. Nationwide
Code information
Lot # 17241278, exp. date Jul-26 17241297, exp. date Jul-26 17241304, exp. date Jul-26 17241315, exp. date Jul-26 17241327, exp. date Jul-26
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0344-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026